Iovance Biotherapeutics (IOVA) to Release Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Wednesday, February 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $1.44 million. During the same quarter in the prior year, the firm posted ($0.64) EPS. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iovance Biotherapeutics Stock Up 0.7 %

NASDAQ IOVA opened at $13.98 on Wednesday. Iovance Biotherapeutics has a fifty-two week low of $3.21 and a fifty-two week high of $18.33. The business has a 50 day moving average price of $13.84 and a two-hundred day moving average price of $9.70. The stock has a market cap of $3.91 billion, a PE ratio of -7.44 and a beta of 0.66.

Insider Activity

In related news, Director Merrill A. Mcpeak purchased 250,000 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average cost of $9.15 per share, for a total transaction of $2,287,500.00. Following the transaction, the director now owns 320,150 shares of the company’s stock, valued at $2,929,372.50. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 10.40% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on IOVA. JMP Securities boosted their price target on Iovance Biotherapeutics from $18.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 20th. StockNews.com raised shares of Iovance Biotherapeutics to a “sell” rating in a research report on Friday, February 2nd. Barclays upped their price target on shares of Iovance Biotherapeutics from $18.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Wells Fargo & Company raised their price objective on shares of Iovance Biotherapeutics from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, March 1st. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.64.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.